symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GRTX,0.2014,1.903277,3984800,8847240,0,0.162-3.59,0.0084,"Galera Therapeutics, Inc.",USD,0001563577,US36338D1081,36338D108,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.galeratx.com,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",Dr. J. Mel Sorensen M.D.,Healthcare,US,31,610 725 1500,2 West Liberty Boulevard,Malvern,PA,19355,0.264762,2.40476,https://financialmodelingprep.com/image-stock/GRTX.png,2019-11-07,False,False,True,False,False
